Member Info for robdance57

Use III - Interactive Investor

I have sent my DRS to my Broker III as I believe they can transfer via the Canadian CDSX

So listing is imminent, not raising cash.Our entitlement of common shares held in escrow apart from the initial release of our entitlement. Remainding shares released over a pre-determined period. The Prospectus explains the release dates. No idea as to the expected listing price as this will be determined by the exchange and the company.

Hello

Well it seems that CRV has totally disapperared the phone number and email address are not in use so where does that leave us shareholders ? Will we get any results in november ?

What is the best way to contact company to find out their intentions?

So where can we hear the recording Thxs

Note that its CIC Group Ltd not CIC Capital Ltd but still interesting .

Be good to here a summary of the companies response to the shareholders questions raised at the meeting

All resolutions passed

So there’s the reason delisted where does that leave us in limbo no doubt !!

According to Chat GPT : InnoMed Tech Ltd. has received conditional approval from the TSX Venture Exchange (TSXV) to list its common shares, contingent upon meeting specific requirements within 90 days from May 20, 2025. This approval is a significant step towards the company's goal of listing on a regulated, designated stock exchange through a Non-Offering Long Form Prospectus.

lse.co.uk The company has filed its final prospectus with the British Columbia Securities Commission, and investors are encouraged to review it for detailed information on the company's business and associated investment risks.

investing.com

Assuming all conditions are met within the specified timeframe, the listing could occur as early as August 2025. However, the exact timing will depend on the completion of all required documentation and regulatory approvals.

TORONTO - InnoMed Tech Ltd., a medical device company, has received conditional approval from the TSX Venture Exchange (TSXV) to list its common shares, a move that marks a significant step for the company’s growth strategy. The approval, contingent upon the company meeting specific TSXV requirements within 90 days from May 20, 2025, was announced today.

The company, known for its focus on medical devices and sciences, is advancing its PureFlowCath Catheter System for Continuous Irrigation (CSCI), designed to mitigate urinary tract infections associated with urinary catheters. InnoMed Tech has been granted various patents, including the European Patent, and aims to bring its CSCI system to market.

InnoMed Tech’s CEO, Rob Rhodes, expressed satisfaction with the conditional listing, viewing it as a reflection of the company’s dedication to shareholder value and its commitment to introducing medical innovations that enhance clinical outcomes.

Investors are encouraged to review the company’s final Non-offering Long Form Prospectus, which has been filed with the British Columbia Securities Commission and contains detailed information about the company’s business and associated investment risks. The Prospectus is accessible on the SEDAR+ website and the company’s official site.

So according to today’s update if the acquisition is successful by the issuance of shares then the market cap on resisting should be in the region of 100 -150 million so a consolidation and additional shares are required. This needs approving at a GM to be call in July so we will then know on the dilution ratio

A 27000 share sell neary1% of the company wish l knew why ????

Https://www.londonstockexchange.com/news-article/market-news/alpha-alternative-assets-fund-update/17068157

Is there a telegra Group for investors ?

The results should be out soon hopefully these will be positive to restore some confidence going forward!

Let’s hope this is not a prerequisite for a fund raise unless at a premium?

Fundraising, Issue of Equity and TVR

twitter sharing button linkedin sharing button facebook sharing button email sharing button sharethis sharing button

Bezant Resources PLC

02 October 2024

A logo for a company Description automatically generated

2 October 2024

Bezant Resources Plc

("Bezant" or the "Company")

£250K Fundraising

Issue of equity to consultant in lieu of fees

Total Voting Rights

Bezant (AIM: BZT), the copper-gold exploration and development company, is pleased to announce a share subscription of £250,000 from Kamino Minerals Limited, a company incorporated in England and Wales ("Kamino Minerals").

In addition, as detailed below the Company will be issuing new Ordinary Shares to a consultant to settle accrued fees due to them.

Fundraising: The Company has raised £250,000 (gross) by way of a share subscription from Kamino Minerals (the "Fundraising") at 0.035 pence per Ordinary Share (the "Fundraising Price") for the issue of 714,285,714 new Ordinary Shares (the "Fundraising Shares") conditional upon admission of the Fundraising Shares to trading on AIM ("Admission"). Pursuant to the Fundraising, in aggregate, 714,285,714 Fundraising Shares will be issued at the Fundraising Price which represents a premium of 59 per cent. to the closing middle market price of an Ordinary Share of 0.022 pence on 1 October 2024, being the latest practicable date prior to this announcement.

Use of Proceeds: The proceeds from the Fundraising are planned to be used:

i) on the Hope Copper-Gold project in Namibia where we await the issue of a mining licence, to support finalisation of technical optimisation work and ongoing negotiations re pre-development contracts, financing offers and the acquisition of existing infrastructure expected to significantly reduce upfront capital expenditure and reduce lead time to production at the Hope & Gorob project.

ii) and also to support other group projects and on corporate overheads and to provide working capital for the Group.

Consultant Shares: The Company is issuing 50,632,911 new Ordinary Shares of 0.002p each (the "Consultancy Fee Shares") at the VWAP of the Bezant share price of 0.0237 pence per Ordinary Share for the 6 months ended 9th September 2024 to settle consultancy fees of £12,000 accrued during this period.

Further Details of the Fundraising: Kamino Minerals will also receive 500,000,000 warrants exercisable at 0.05 pence per ordinary share exercisable on or before 31 January 2025 ("Fundraising Warrants"). The Fundraising Shares represent approximately 5.81 per cent. of the Company's enlarged issued share capital as enlarged by the issue of the Fundraising Shares and the Consultancy Fee Shares.

The Fundraising Shares and the Consultancy Fee Shares will be fully paid and rank pari passu in all respects with the Company's existing Ordinary Shares.

Application to trading on AIM: The Fundraising is conditional on Admission. Application

If you have a £1000 loss and a £1000 gain then no profit made so no tax to pay